Find clinical trials for Acute Myeloid Leukemia (AML) in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near Paris, Île-de-France, FRA:
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse aft...
Phase 1
Paris, France and 12 other locations
azacitidine combination is susceptible to improve the prevention of AML relapse, which remains a major issue in the study population. We ass...
Phase 2
Paris, France and 19 other locations
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML...
Phase 3
Paris, Île-de-France Region, France and 114 other locations
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Paris, France and 27 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Paris, Île-de-France Region, France and 89 other locations
will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...
Phase 1, Phase 2
Paris, France and 43 other locations
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain ...
Phase 3
Paris, France and 148 other locations
Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the ...
Phase 3
Paris, France and 52 other locations
inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refr...
Phase 1, Phase 2
Paris, Île-de-France, France and 34 other locations
with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...
Phase 1, Phase 2
Paris, France and 48 other locations
Clinical trials
Research sites
Resources
Legal